Yahoo Finance • 17 days ago
Corcept Therapeutics Incorporated MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe en... Full story
Yahoo Finance • 3 months ago
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript February 15, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.28, expectations were $0.25. Corcept Therapeutics Incorpo... Full story
Yahoo Finance • 5 months ago
A plunge in Corcept Therapeutics shares in response to a disappointing court ruling offers a great chance to buy the shares, according to one analyst team. Last week, a court ruled that Teva Pharmaceutical Industries a maker of generic dru... Full story
Yahoo Finance • 7 months ago
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism an... Full story
Yahoo Finance • 7 months ago
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, a... Full story
Yahoo Finance • 7 months ago
MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, a... Full story
Yahoo Finance • 7 months ago
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2023. The company will al... Full story
Yahoo Finance • a year ago
Key Insights The projected fair value for Corcept Therapeutics is US$17.54 based on 2 Stage Free Cash Flow to Equity Corcept Therapeutics is estimated to be 27% overvalued based on current share price of US$22.25 The US$30.67 analyst pric... Full story
Yahoo Finance • a year ago
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel monotherapy Confirmatory Phase 3 ROSELLA trial und... Full story
Yahoo Finance • a year ago
Participants Atabak Mokari; CFO & Treasurer; Corcept Therapeutics Incorporated Gary Charles Robb; Chief Business Officer & Secretary; Corcept Therapeutics Incorporated Joseph K. Belanoff; Co-Founder, President, CEO & Director; Corcept T... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic a... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic,... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
Yahoo Finance • a year ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Inc. (“Corcept” or the “Company”) (NASDAQ: CORT)... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
Yahoo Finance • a year ago
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
Yahoo Finance • 2 years ago
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic an... Full story
Home
Money Search
Trending Sports
Gallery
Shop
Blog
Examples
Data & Glossary
Elements of Bball
Harden Maze
About
